Skip to content
BY-NC-ND 3.0 license Open Access Published by De Gruyter Open Access February 21, 2014

Bevacizumab cured age-related macular degeneration (AMD) via down-regulate TLR2 pathway

  • Zhi Wang EMAIL logo , Bao Qiao , Guo Li , Shi Li , Li Wang and Ying Dong
From the journal Open Life Sciences

Abstract

AMD is the main cause of visual impairment in people over 50 years of age and the most common cause of blindness. In recent years, the use of bevacizumab to treat neovascular AMD has become a preferred treatment in the United States. However, whether bevacozumab is available for RPE or AMD patients is unknown. We firstly indicate that Pam3CSK4 (P3C) activates TLR2 pathway during ARPE-19 apoptosis as determined by western blotting. And then, the expression of MyD88, NF-κB, p-IKK in primary RPE cells from AMD patients is significantly down-regulated after treatment with 50 µg L−1 Bevacizumab. Therefore, our data shows that MyD88 is involved in the TLR2 pathway in ARPE-19 cell apoptosis resulting from Pam3CSK4 (P3C). And more importantly, our findings suggested that Bevacizumab cured age-related macular degeneration (AMD) via down-regulate Toll—like receptor 2 (TLR2) pathway in RPE from AMD patients.

Keywords: Bevacizumab; AMD; TLR2; RPE

[1] Martin D.F., Maguire M.G., Ying G.S., Grunwald J.E., Fine S.L., Jaffe G.J., Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration, N. Engl. J. Med., 2011, 364, 1897–1908 http://dx.doi.org/10.1056/NEJMicm100560510.1056/NEJMicm1005605Search in Google Scholar PubMed

[2] Jager R.D., Mieler W.F., Miller J.W., Age-related macular degeneration, N. Engl. J. Med., 2008, 358, 2606–2617 http://dx.doi.org/10.1056/NEJMra080153710.1056/NEJMra0801537Search in Google Scholar PubMed

[3] Cipriani V., Matharu B.K., Khan J.C., Shahid H., Stanton C.M., Hayward C., et al., Genetic variation in complement regulators and susceptibility to agerelated. macular degeneration, Immunobiology, 2012, 217, 158–161 http://dx.doi.org/10.1016/j.imbio.2011.09.00210.1016/j.imbio.2011.09.002Search in Google Scholar PubMed PubMed Central

[4] Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al., Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N. Engl. J. Med., 2004, 350, 2335–2342 http://dx.doi.org/10.1056/NEJMoa03269110.1056/NEJMoa032691Search in Google Scholar PubMed

[5] Meyer C.H., Holz F.G., Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab, Eye (Lond), 2011, 25, 661–672 http://dx.doi.org/10.1038/eye.2011.6610.1038/eye.2011.66Search in Google Scholar PubMed PubMed Central

[6] Luo Y., Zhuo Y., Fukuhara M., Rizzolo L.J., Effects of culture conditions on heterogeneity and the apical junctional complex of the ARPE-19 cell line, Invest. Ophthalmal. Vis. Sci., 2006, 47, 3644–3655 http://dx.doi.org/10.1167/iovs.06-016610.1167/iovs.06-0166Search in Google Scholar PubMed

[7] Hageman G.S., Mullins R.F., Molecular composition of drusen as related to substructural phenotype, Mol. Vis., 1999, 3, 25–28 Search in Google Scholar

[8] Algvere P.V., Seregard S., Drusen maculopathy: a risk factor for AMD. Can we prevent visual loss?, Acta Ophthalmol. Scand., 2003, 81, 427–429 http://dx.doi.org/10.1034/j.1600-0420.2003.00157.x10.1034/j.1600-0420.2003.00157.xSearch in Google Scholar PubMed

[9] Bok D., New insights and new approaches toward the study of age-related macular degeneration, Proc. Natl. Acad. Sci. U.S.A., 2002, 99, 14619–14621 http://dx.doi.org/10.1073/pnas.24260789910.1073/pnas.242607899Search in Google Scholar PubMed PubMed Central

[10] An E., Lu X., Flippin J., Devaney J.M., Halligan B., Hoffman E.P., et al., Secreted Proteome Profiling in Human RPE Cell Cultures Derived from Donors with Age Related Macular Degeneration and Age Matched Healthy Donors, J. Proteome. Res., 2006, 5, 2599–2610 http://dx.doi.org/10.1021/pr060121j10.1021/pr060121jSearch in Google Scholar PubMed

[11] Uh A., Simmons C.F., Bresee C., Khoury N., Gombart A.F., Nicholson R.C., et al., MyD88 and TRIF mediate the cyclic adenosine monophosphate (cAMP) induced corticotropin releasing hormone (CRH) expression in JEG3 choriocarcinoma cell line, Reprod. Biol. Endocrinol., 2009, 7, 74 http://dx.doi.org/10.1186/1477-7827-7-7410.1186/1477-7827-7-74Search in Google Scholar PubMed PubMed Central

[12] Zhang F.X., Kirschning C.J., Mancinelli R., Xu X.P., Jin Y., Faure E., et al., Bacterial lipopolysaccharide activates nuclear factor-kappaB through interleukin-1 signaling mediators in cultured human dermal endothelial cells and mononuclear phagocytes, J. Biol. Chem., 1999, 274, 7611–7619 http://dx.doi.org/10.1074/jbc.274.12.761110.1074/jbc.274.12.7611Search in Google Scholar

[13] Bird A.C., Bressler N.M., Bressler S.B., An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group., Surv. Ophthalmol., 1995, 39, 367–374 http://dx.doi.org/10.1016/S0039-6257(05)80092-X10.1016/S0039-6257(05)80092-XSearch in Google Scholar

[14] Beatty S., Koh H., Phil M., Henson D., Boulton M., The role of oxidative stress in the pathogenesis of age-related macular degeneration, Surv. Ophthalmol., 2000, 45, 115–134 http://dx.doi.org/10.1016/S0039-6257(00)00140-510.1016/S0039-6257(00)00140-5Search in Google Scholar

[15] Uh A., Nicholson R.C., Gonzalez G.V., Simmons C.F., Gombart A., Smith R., et al., Lipopolysaccharide stimulation of trophoblasts induces corticotropinreleasing hormone expression through MyD88, Am. J. Obstet. Gynecol., 2008, 199, 317.e1–6. 10.1016/j.ajog.2008.06.091Search in Google Scholar PubMed PubMed Central

[16] Uh A., Simmons C.F., Bresee C., Khoury N., Gombart A.F., Nicholson R.C., et al., MyD88 and TRIF mediate the cyclic adenosine monophosphate (cAMP) induced corticotropin releasing hormone(CRH) expression in JEG3 choriocarcinoma cell line, Reprod. Biol. Endocrinol., 2009, 7, 74 http://dx.doi.org/10.1186/1477-7827-7-7410.1186/1477-7827-7-74Search in Google Scholar PubMed PubMed Central

[17] Kumar M.V., Nagineni C.N., Chin M.S., Hooks J.J., Detrick B., Innate immunity in the retina: Toll-like receptor (TLR) signaling in human retinal pigment epithelial cells, J. Neuroimmunol., 2004, 153, 7–15 http://dx.doi.org/10.1016/j.jneuroim.2004.04.01810.1016/j.jneuroim.2004.04.018Search in Google Scholar PubMed PubMed Central

[18] Yu F.S., Hazlett L.D., Toll-like Receptors and the Eye, Invest. Ophthalmol. Vis. Sci., 2006, 47, 1255–1263 http://dx.doi.org/10.1167/iovs.05-095610.1167/iovs.05-0956Search in Google Scholar PubMed PubMed Central

[19] Martin P.M., Ananth S., Cresci G., Roon P., Smith S., Ganapathy V., Expression and localization of GPR109A (PUMA-G/HM74A) mRNA and protein in mammalian retinal pigment epithelium, Mol. Vis., 2009, 15, 362–372 Search in Google Scholar

[20] Miller K., Wang M., Gralow J., Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer, N. Engl. J. Med., 2007, 357, 2666–2676 http://dx.doi.org/10.1056/NEJMoa07211310.1056/NEJMoa072113Search in Google Scholar PubMed

[21] Brechner R.J., Rosenfeld P.J., Babish J.D., Caplan S., Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 Medicare feefor- service Part B claims file, Am. J. Ophthalmol., 2011, 151, 887–895 http://dx.doi.org/10.1016/j.ajo.2010.11.01710.1016/j.ajo.2010.11.017Search in Google Scholar PubMed

[22] Kook D., Wolf A., Kreutzer T., Neubauer A., Strauss R., Ulbig M., et al., Long-term effect of intravitreal bevacizumab(Avastin) in patients with chronic diffuse diabetic macular edema, Retina, 2008, 28, 1053–1060 http://dx.doi.org/10.1097/IAE.0b013e318176de4810.1097/IAE.0b013e318176de48Search in Google Scholar PubMed

[23] Waintraub S.E., Tuchman V., The role of maintenance bevacizumab in patients with metastatic breast cancer treated with chemotherapy and bevacizumab upon achieving complete response or maximal radiologic response with stable disease, J. Clin. Oncol., 2008, 26(20 suppl), 120–122 10.1200/jco.2008.26.15_suppl.12022Search in Google Scholar

Published Online: 2014-2-21
Published in Print: 2014-5-1

© 2014 Versita Warsaw

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Downloaded on 29.3.2024 from https://www.degruyter.com/document/doi/10.2478/s11535-014-0290-5/html
Scroll to top button